Willem Jacobus De Lange

Has grant

Scientist II

University of Wisconsin-Madison
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Treating Hearts at Risk for Cardiomyopathy: Leveraging Human iPSC Disease Models

Open Date: 2025-06-01

Close Date: 2026-05-01

Grant: Close

Developing Novel Atrial-like Engineered Cardiac Tissue for Modeling Cardiac Pressure Overload and Atrial Fibrillation

Open Date: 2022-07-01

Close Date: 2023-06-01

Grant: Close

Mechanism of regulation of cardiac contraction by phosphorylation of myosin binding protein C

Open Date: 2018-07-01

Close Date: 2023-06-30

Grant: Close

Top-Down Proteomics of Myofilaments in Heart Failure

Open Date: 2011-08-05

Close Date: 2022-11-30

Grant: Close

Murine 3D Engineered Tissue Model of Human MYBPC3 Mutations

Open Date: 2011-06-13

Close Date: 2017-05-31

Articles (7)

Year:

2026

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Truncation mutations in cardiac myosin binding protein C (cMyBP-C) are common causes of hypertrophic cardiomyopathy (HCM). Heterozygous carriers present with classical HCM, while homozygous carriers present with early onset HCM that rapidly progress to heart failure. We used CRISPR-Cas9 to introduce heterozygous (cMyBP-C+/−) and homozygous (cMyBP-C−/−) frame-shift mutations into MYBPC3 in human iPSCs. Cardiomyocytes derived from these isogenic lines were used to generate cardiac micropatterns and engineered cardiac tissue constructs (ECTs) that were characterized for contractile function, Ca2+-handling, and Ca2+-sensitivity. While heterozygous frame shifts did not alter cMyBP-C protein levels in 2-D cardiomyocytes, cMyBP-C+/− ECTs were haploinsufficient. cMyBP-C−/− cardiac micropatterns produced increased strain with normal Ca2+-handling. After 2 wk of culture in ECT, contractile function was similar between the three genotypes; however, Ca2+-release was slower in the setting of reduced or absent cMyBP-C. At 6 wk in ECT culture, the Ca2+-handling abnormalities became more pronounced in both cMyBP-C+/− and cMyBP-C−/− ECTs, and force production became severely depressed in cMyBP-C−/− ECTs. RNA-seq analysis revealed enrichment of differentially expressed hypertrophic, sarcomeric, Ca2+-handling, and metabolic genes in cMyBP-C+/− and cMyBP-C−/− ECTs. Our data suggest a progressive phenotype caused by cMyBP-C haploinsufficiency and ablation that initially is hypercontractile, but progresses to hypocontractility with impaired relaxation. The severity of the phenotype correlates with the amount of cMyBP-C present, with more severe earlier phenotypes observed in cMyBP-C−/− than cMyBP-C+/− ECTs. We propose that while the primary effect of cMyBP-C haploinsufficiency or ablation may relate to myosin crossbridge orientation, the observed contractile phenotype is Ca2+-mediated.

Year:

2023

Year:

2023

Collaborators (8)

Alexey Glukhov

Associate Professor

Imperial College London

UNITED KINGDOM
View details

Morgan Mann

Assistant Professor (CHS)

University of Wisconsin-Madison

UNITED STATES
View details

J. Carter Ralphe

University of Wisconsin-Madison

UNITED STATES
View details

Christopher Coe

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Eric Schmuck

Research Assistant Professor

University of Wisconsin-Madison

UNITED STATES
View details

Timothy Kamp

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Di Lang

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Angela Greenman

University of Wisconsin-Madison

UNITED STATES
View details